Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 1306 Download: 142 Citation: 1

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 1206 Download: 77

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 1577 Download: 130 Citations: 3

Editorial

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 798 Download: 35

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 693 Download: 40

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 2051 Download: 110 Citations: 3

Editorial

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 1419 Download: 45

Review

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):790-801. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0070

View: 3898 Download: 388 Citations: 23

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 1924 Download: 69

Original Article

Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis

Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding

Clin Mol Hepatol. 2021;27(2):329-345. Published online January 20, 2021

DOI: https://doi.org/10.3350/cmh.2020.0261

View: 4805 Download: 193 Citations: 12

Review

Recent research trends and updates on nonalcoholic fatty liver disease

Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn

Clin Mol Hepatol. 2019;25(1):1-11. Published online August 8, 2018

DOI: https://doi.org/10.3350/cmh.2018.0037

View: 16748 Download: 696 Citations: 54

Original Article

Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis

Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki

Clin Mol Hepatol. 2018;24(1):61-76. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0030

View: 8011 Download: 159 Citations: 22

Case Report

Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy

Eun Hui Sim, Jung Hyun Kwon, Se Young Kim, Seung Min Jung, Lee-So Maeng, Jeong Won Jang, Kyu Won Chung

Clin Mol Hepatol. 2012;18(4):404-410. Published online December 21, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.4.404

View: 6449 Download: 77 Citations: 13

3

Validity and reliability of the nonalcoholic fatty Liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors

Kyung-Hun Lee, M.D., Sang Hoon Park, M.D., Yu Jin Kim, M.D., Kyung Rim Huh, M.D., Kwang Seon Min M.D., Sun-Young Jun M.D., Kyoung Oh Kim, M.D., Cheol Hee Park, M.D., Taeho Hahn, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung-Seok Lee, M.D., Choong Kee Park, M.D.

Clin Mol Hepatol. 2010;16(1):29-37. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.29

View: 4616 Download: 47 Citations: 2

Current status of Liver diseases in Korea: nonalcoholic fatty Liver disease

Sang Hoon Park

Clin Mol Hepatol. 2009;15(60):34-39. Published online December 31, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S34

View: 6622 Download: 43 Citations: 19

2

Pathology of nonalcoholic steatohepatitis

Yoon Mi Jeen , So Young Jin

Clin Mol Hepatol. 2009;15(2):122-130. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.122

View: 4613 Download: 54 Citations: 3

5

Nonalcoholic Steatohepatitis

So-Young Jin

Clin Mol Hepatol. 2006;12(3):455-459. Published online January 1, 2000

View: 2335 Download: 20

3

Antioxidant Status in Nonalcoholic Steatohepatitis

Kyung Sik Park, M.D., Byoung Kuk Jang, M.D., Ki Min Kwon, M.D., Woo Jin Chung, M.D., Kwang Bum Cho, M.D., Jae Seok Hwang, M.D., Sung Hoon Ahn, M.D., Kyo Cheol Mun, M.D. and Young Hwan Kim, M.D.

Clin Mol Hepatol. 2005;11(2):135-143. Published online January 1, 2000

View: 2344 Download: 26

Relationship between the Severity of Liver Damage and the Serum Leptin Level for Nonalcoholic Fatty Liver Disease

Kyoung Oh Kim, M.D., Sang Hoon Park, M.D., Cheol Hee Park, M.D., Tai Ho Han, M.D., Kyo-Sang Yoo, M.D., Jong Hyeok Kim, M.D., Myung Seok Lee, M.D., Dong Jun Kim, M.D., Choong Kee Park, and Hyun-Deuk Cho, M.D.

Clin Mol Hepatol. 2005;11(1):51-58. Published online January 1, 1970

View: 2315 Download: 35

The Prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease

Ki Won Moon, M.D., Joung Muk Leem, M.D., Sang Seok Bae, M.D., Ki Man Lee, M.D., Seok Hyung Kim, M.D.*, Hee Bok Chae, M.D., Seon Mee Park, M.D. and Sei Jin Youn, M.D.

Clin Mol Hepatol. 2004;10(3):197-206. Published online January 1, 1970

View: 2829 Download: 56

Original Article

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Received October 22, 2022 Accepted March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0330 [Accepted]

View: 492 Download: 50

1 |

Viewed By 4171	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2768	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2516	Recent updates on the management of autoimmune hepatitis
Viewed By 2490	Management of refractory ascites
Viewed By 2465	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Cited By 100	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 44	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search